were diagnosed during the follow-up period. However, both relatives did not display any of the investigated serum antibodies (p = 1). Discussion: The fi ndings of our pilot study argue against a role of serum antibodies as a marker of disease susceptibility in fi rst-degree relatives of patients with infl ammatory bowel disease. However, these data have to await confi rmation in larger ideally prospective multicenter studies before defi nite conclusions can be drawn.
Introduction
Various serum antibodies have been described to occur in Crohn's disease or ulcerative colitis. Although not exclusively present in infl ammatory bowel disease, the most prominent examples to date are antibodies against Saccharomyces cerevisiae (ASCA) and perinuclear-antineutrophil cytoplasmic autoantibodies (p-ANCA). ASCA are regarded as serologic markers for Crohn's disease and can be found in about two thirds of these patients [1] [2] [3] , whereas p-ANCA occur in 45 to 80% of patients with ulcerative colitis [4] [5] [6] [7] . As opposed to ASCA, which were
Key Words
First-degree relatives ؒ Crohn's disease ؒ Ulcerative colitis ؒ Serum antibodies ؒ Disease susceptibility Abstract Introduction: Various disease-specifi c serum antibodies were described in patients with infl ammatory bowel disease and their yet healthy fi rst-degree relatives. In the latter, serum antibodies are commonly regarded as potential markers of disease susceptibility. The present long-term follow-up study evaluated the fate of antibody-positive fi rst-degree relatives. Patients and Methods: 25 patients with Crohn's disease, 19 patients with ulcerative colitis and 102 fi rst-degree relatives in whom presence of ASCA, pANCA, pancreatic-and goblet-cell antibodies had been assessed were enrolled. The number of incident cases with infl ammatory bowel disease was compared between antibody-positive and antibodynegative fi rst-degree relatives 7 years after storage of serum samples. Results: 34 of 102 (33%) fi rst-degree relatives were positive for at least one of the studied serum antibodies. In the group of fi rst-degree relatives, one case of Crohn's disease and one case of ulcerative colitis recently described also in association with HLA-B27 associated spondylarthropathies [8, 9] , antibodies against exocrine pancreas (PAB) are highly disease-specifi c [10] , but are present only in about one third of patients with Crohn's disease [11] . Due to their lower prevalence, PAB are less attractive serologic marker for Crohn's disease compared to ASCA. Autoantibodies against intestinal goblet cells (GAB) are present in about one third of patients with Crohn's disease and ulcerative colitis [12] .
Despite intense research during the last years, the implication of these serum antibodies in infl ammatory bowel disease remains enigmatic. ASCA [1] , p-ANCA [6, 13] and GAB [12] are found in increased prevalence also in fi rst degree relatives of patients with infl ammatory bowel disease, in particular if the index patient displays the respective antibody. PAB were also associated with the occurrence of infl ammatory bowel disease in fi rst-degree relatives of patients with Crohn's disease [14] . On the other hand, fi rst-degree relatives of patients with infl ammatory bowel disease display an increased disease susceptibility compared to the general population and, thus, it has been hypothesized that the aforementioned serum markers might represent enhanced genetic or environmental disease susceptibility [15] . However, if this assumption is correct, one would expect that antibody-positive fi rst-degree relatives are more likely to develop infl ammatory bowel disease than antibody-negative fi rst-degree relatives. The present study addressed this issue by comparing the number of incident cases of Crohn's disease and ulcerative colitis in a cohort of fi rst-degree relatives of patients with infl ammatory bowel disease after a follow-up period of 7 years.
Patients and Methods
Twenty-fi ve patients with Crohn's disease, 19 patients with ulcerative colitis and 102 fi rst-degree relatives in whom presence of ASCA, p-ANCA, PAB and GAB had been assessed were enrolled in this study. ASCA IgA and ASCA IgG have been detected by ELISA (Medizym, for details, see ref. [1] ) whereas for the remainder of antibodies indirect immunofl uorescence had been performed as described in detail elsewhere [11, 12] . Seven years after collection of serum samples, fi rst degree-relatives were interviewed applying a standardized questionnaire, which assessed the following symptoms: Diarrhea of more than three days duration, anal discharge of mucus or blood, weight loss, abdominal pain, ocular infl ammation, cutaneous nodules or ulcerations and arthralgias. Additionally, in case of newly diagnosed infl ammatory bowel disease the medical charts were reviewed. The diagnosis of Crohn's disease or ulcerative colitis was based on conventional clinical, endoscopic, histopathologic and radiological criteria. We aimed to contact all relatives. If this was not possible, family members were asked about the fate of relatives who took not part in this study. Antibody-positive and antibody-negative fi rst-degree relatives were compared in terms of number of incident cases with infl ammatory bowel disease at 7 years after storage of serum samples. Statistical evaluation was carried out using Fisher's exact test.
Results
A total of 40 families with one affected individual and 2 families with 2 affected individuals were included in the study. In 11 of the 42 families, one unaffected fi rstdegree relative per family was enrolled. In 12 families 2, in 13 families 3, and 4 and 5 fi rst-degree relatives were enrolled in 2 and 4 families, respectively. The baseline and clinical characteristics of index patients and the demographics of fi rst-degree relatives are depicted in tables 1 and 2 , respectively.
Of the 25 patients with Crohn's disease, 9 patients were positive for ASCA IgG (5 of them displayed also ASCA IgA), 10 patients were positive for PAB, 6 patients displayed GAB and 1 patient was positive for p-ANCA. Eight of the 25 patients included in this study were posi- tive for more than one of the antibodies tested. Of the 19 patients with ulcerative colitis 7 were positive for p-ANCA and 10 patients displayed GAB. Of these, three were positive for both p-ANCA and GAB ( table 3 ) . Among fi rst-degree relatives of patients with infl ammatory bowel disease, 34 of 102 (33%) were positive for at least one of the studied serum antibodies (13 for ASCA IgA, ASCA IgG or both, 3 for p-ANCA, 3 for PAB and 17 for GAB) ( table 3 ). In 2 fi rst-degree relatives, more than one serum antibody was detectable, one of them was positive for both GAB and ASCA IgG and the other displayed GAB and p-ANCA. One new case of Crohn's disease and one new case of ulcerative colitis were diagnosed in the group of fi rst-degree relatives during the follow-up period. In both cases the diagnosis was concordant with the respective index patient, which means that the patient and the relative displayed the same type of infl ammatory bowel disease. However, both relatives did not display any of the investigated serum antibodies (p = 1 compared to unaffected relatives). In the remainder of fi rst-degree relatives, symptoms suggestive of yet undiagnosed infl ammatory bowel disease were not detected.
Discussion
Previous studies showed occurrence of various antibodies such as p-ANCA [6, 13] , ASCA [1] , antibodies against endothelial cells [16] or antinuclear antibodies [17] Table 3 . Prevalence of serum antibodies in index patients with infl ammatory bowel disease and their fi rst-degree relatives ative colitis, but also in their still healthy fi rst-degree relatives, who display a signifi cantly increased risk to develop infl ammatory bowel disease. Therefore, an implication of these antibodies in infl ammatory bowel disease comprises their use as potential markers of disease susceptibility. In line with this concept is the observation that infl ammatory bowel disease-specifi c antibodies are -with few exceptions, such as endothelial cell antibodies [16] -not found in increased prevalence in infectious enterocolitis [1] or in spouses of patients [17] . However, due to the lack of long-term follow-up data about the course of antibody-positive fi rst-degree relatives, the potential role of these serum markers in refl ecting disease susceptibility still remains speculative so far. The results of our study do also not sustain this hypothesis, although this is, to the best of our knowledge, the fi rst approach addressing the issue. However, our retrospective study bears some limitations: First-degree relatives with an unremarkable history were offered a screening colonoscopy if they were older than 50 years, but in the remainder an endoscopic investigation was not performed due to ethical reasons. Thus, only 25 of the 102 fi rst-degree relatives underwent colonoscopy during the follow-up period.
With the exception of the two newly diagnosed cases with infl ammatory bowel disease no signs compatible with yet undiagnosed Crohn's disease or ulcerative colitis were observed in this group. However, comparable to previous trials assessing the presence of ASCA in patients with HLA-B27 associated spondylarthropathies [8, 9] , we cannot rule out that subclinical cases of infl ammatory bowel disease might have been missed in the remainder of fi rstdegree relatives. A potential observation bias could result from the fact that we might have missed relatives who were not able or willing to take part in the study. In addition, the follow-up period might have been too short, and this study will probably have to be repeated in an extended population within a few years. Whether serum markers are associated with specifi c clinical phenotypes in infl ammatory bowel disease, remains a matter of ongoing research [18] [19] [20] . However, it is possible, that certain subtypes of Crohn's disease or ulcerative colitis which predispose to the presence of serum antibodies were underrepresented in the population studied herein. Finally, it should be pointed out that at least in our hands, two of the investigated antibodies namely p-ANCA and PAB, did not show a familial occurrence [11] , which is in the case of p-ANCA in accordance with the majority of literature data [for overview, see 21] . To the best of our knowledge, PAB were never reported to occur familial. Nevertheless, PAB were regarded in the analysis due to the observation of some antibody-positive fi rst-degree relatives which seem to be prone to develop Crohn's disease [14] . The frequencies of serum antibodies in healthy unrelated controls ranged between 2 and 4% [1, 11, 12] and the latter were not included in the present trial. In summary, our retrospective pilot study does not sustain the putative role of serum antibodies as markers of disease susceptibility in infl ammatory bowel disease. The fact that none of the antibody-positive relatives developed clinical symptoms of infl ammatory bowel disease is reassuring. However, due to the above mentioned limitations these data certainly have to await confi rmation in larger, ideally prospectively designed multi-centre trials before defi nitive conclusion can be drawn.
